Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

PHARMACIE SOMMIER : revenue, balance sheet and financial ratios

PHARMACIE SOMMIER is a French company founded 11 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in OCTEVILLE-SUR-MER (76930), this company of category PME shows in 2022 a revenue of 2.5 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE SOMMIER (SIREN 807505730)
Indicator 2025 2024 2023 2022 2018
Revenue N/C N/C N/C 2 534 581 € N/C
Net income 188 481 € 272 161 € 237 865 € 239 619 € 218 996 €
EBITDA N/C N/C N/C 333 639 € N/C
Net margin N/C N/C N/C 9.5% N/C

Revenue and income statement

In 2025, PHARMACIE SOMMIER generates positive net income of 188 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2018-2025: 219 k€ -> 188 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

188 481 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 56%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 58%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

55.842%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

58.357%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

92.7%

Solvency indicators evolution
PHARMACIE SOMMIER

Sector positioning

Debt ratio
55.84 2025
2023
2024
2025
Q1: 13.57
Med: 49.47
Q3: 128.28
Average +17 pts over 3 years

In 2025, the debt ratio of PHARMACIE SOMMIER (55.84) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
58.36% 2025
2023
2024
2025
Q1: 33.69%
Med: 53.88%
Q3: 72.26%
Good -17 pts over 3 years

In 2025, the financial autonomy of PHARMACIE SOMMIER (58.4%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 243.81. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

243.815

Liquidity indicators evolution
PHARMACIE SOMMIER

Sector positioning

Liquidity ratio
243.81 2025
2023
2024
2025
Q1: 131.48
Med: 182.6
Q3: 258.72
Good

In 2025, the liquidity ratio of PHARMACIE SOMMIER (243.81) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE SOMMIER

Positioning of PHARMACIE SOMMIER in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of PHARMACIE SOMMIER is estimated at 2 994 043 € (range 2 031 771€ - 4 698 065€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
2031k€ 2994k€ 4698k€
2 994 043 € Range: 2 031 771€ - 4 698 065€
NAF 5 année 2025

Valuation method used

Net Income Multiple
188 481 € × 15.9x = 2 994 043 €
Range: 2 031 772€ - 4 698 066€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE SOMMIER with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE SOMMIER

What is the revenue of PHARMACIE SOMMIER ?

The revenue of PHARMACIE SOMMIER in 2022 is 2.5 M€.

Is PHARMACIE SOMMIER profitable?

Yes, PHARMACIE SOMMIER generated a net profit of 188 k€ in 2025.

Where is the headquarters of PHARMACIE SOMMIER ?

The headquarters of PHARMACIE SOMMIER is located in OCTEVILLE-SUR-MER (76930), in the department Seine-Maritime.

Where to find the tax return of PHARMACIE SOMMIER ?

The tax return of PHARMACIE SOMMIER is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE SOMMIER operate?

PHARMACIE SOMMIER operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.